Pharmaceutical composition used in kit for treatment or prevention of uterine disorders preferably uterine fibroids, and adenomyosis, comprises dydrogesterone or its ester(s), and aromatase inhibitor or salts along with one or more pharmaceutically acceptable excipients
	KUMAR A; RAI K S
	2023-09-18
专利权人	MANKIND PHARMA LTD (MANK-Non-standard)
申请日期	2023-09-18
专利号	IN202311062580-A
成果简介	NOVELTY - Pharmaceutical composition comprises dydrogesterone or its ester(s), and aromatase inhibitor or salts along with one or more pharmaceutically acceptable excipients. USE - Pharmaceutical composition used in kit for treatment or prevention of uterine disorders preferably uterine fibroids, adenomyosis, endometriosis, heavy menstrual bleeding, or pain associated with uterine fibroids, and other related disorders. No biological data given. ADVANTAGE - The pharmaceutical composition comprises excipients that are useful in preparing a dosages form are generally safe, non-toxic, and are acceptable for veterinary as well as human pharmaceutical use. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for kit, which comprises: (a) composition comprising dydrogesterone and pharmaceutically acceptable excipients; (b) composition comprising letrozole and pharmaceutically acceptable excipients, where composition of dydrogesterone and composition of letrozole are administered either simultaneously, concurrently, alternately and/or sequentially.
IPC 分类号	A61K-031/4196 ; A61K-031/513 ; A61K-039/395 ; A61P-015/00 ; A61P-035/00
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20362
专题	中国科学院新疆生态与地理研究所
作者单位	MANKIND PHARMA LTD (MANK-Non-standard)
推荐引用方式 GB/T 7714	KUMAR A,RAI K S. Pharmaceutical composition used in kit for treatment or prevention of uterine disorders preferably uterine fibroids, and adenomyosis, comprises dydrogesterone or its ester(s), and aromatase inhibitor or salts along with one or more pharmaceutically acceptable excipients. IN202311062580-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。